Antiretroviral Drug Resistance Testing in Adults With HIV Infection
- 24 June 1998
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 279 (24) , 1984-1991
- https://doi.org/10.1001/jama.279.24.1984
Abstract
Objectives.— To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice. Participants.— The International AIDS Society-USA assembled a panel of 13 physicians with expertise in basic science, clinical research, and patient care relevant to HIV resistance to antiretroviral drugs. Evidence.— We reviewed available data from published reports and presented at national and international research conferences. Basic science research, clinical trial results, and expert opinions were used to form the basis of this report. Data on methods for and characteristics of specific genotypic and phenotypic assays were obtained from manufacturers and service providers. Consensus Process.— The panel met regularly between October 1997 and April 1998. Panel subgroups developed and discussed different sections of the report before discussing them with the entire panel. Conclusions and suggested approaches to the use of resistance testing were determined by group consensus. Conclusions.— Plasma HIV RNA level and CD4+ cell count are the primary values that should be used to guide the initiation of antiretroviral therapy and subsequent changes in therapy. Possible causes of treatment failure other than development of drug resistance that should be considered are adherence, drug potency, and pharmacokinetic issues. Genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may prove useful for individual patient management. Assays under development need validation, standardization, and a clearer definition of their clinical roles. Possible current roles of resistance testing for choosing an initial regimen or changing antiretroviral therapy, as well as possible implications of the presence or absence of phenotypic resistance and genotypic changes, are discussed.Keywords
This publication has 41 references indexed in Scilit:
- HIV-1 Reverse Transcriptase Codon 215 Mutation in Plasma RNA: Immunologic and Virologic Responses to ZidovudineJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing complianceAIDS Care, 1996
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Distinct but Related Human Immunodeficiency Virus Type 1 Variant Populations in Genital Secretions and BloodAIDS Research and Human Retroviruses, 1996
- Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′,3′-Dideoxynucleoside 5′-TriphosphatesJournal of Biological Chemistry, 1995
- Evaluation of Safety and Efficacy of 3TC (Lamivudine) in Patients with Asymptomatic or Mildly Symptomatic Human Immunodeficiency Virus Infection: A Phase I/II StudyThe Journal of Infectious Diseases, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Genotypic And Phenotypic Analysis Of Human Immunodeficiency Virus Type 1 Isolates From Patients On Prolonged Stavudine TherapyThe Journal of Infectious Diseases, 1994
- Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene MutationsThe Journal of Infectious Diseases, 1994
- Development and significance of zidovudine resistance in children infected with human immunodeficiency virusThe Journal of Pediatrics, 1993